The civil society organization Swasthya Adhikar Manch (SAM) is urging for increased transparency in the governance of clinical trials and the compensation processes for individuals affected by these trials. Their call to action highlights ongoing concerns around the efficacy of regulatory frameworks that were established following their initial Public Interest Litigation in 2012.
Background of SAM’s Advocacy
In 2012, SAM approached the Supreme Court with significant apprehensions regarding the oversight of clinical trials in India. The group pointed out the lack of a robust regulatory framework at that time, which raised alarms about participant safety and ethical considerations.
In response to their petition, the Supreme Court mandated several reforms aimed at improving the regulatory landscape. These included the compulsory registration of Ethics Committees, a strengthened informed consent procedure—now requiring video recordings—and the introduction of the New Drugs and Clinical Trials Rules in 2019. These rules aimed to enhance reporting of deaths and Serious Adverse Events (SAEs) and established a multi-layered approval mechanism.
Continuing Concerns
Despite these advancements, SAM asserts that significant gaps remain in the implementation of these regulations. They claim that violations of the established guidelines are still prevalent, undermining the intended protections for trial participants.
During a recent court hearing regarding their petition, senior advocates representing SAM, Sanjay Parikh and Abhimanyu Shrestha, articulated these ongoing issues. They emphasized the need for a more stringent regulatory framework that genuinely protects participants in clinical trials.
Alarming Statistics
SAM has compiled concerning data illustrating the scale of the issue. Based on government submissions to the court, Right to Information (RTI) responses, and the Ministry of Health and Family Welfare’s statements in the Rajya Sabha, the organization reported a staggering total of 8,205 deaths and 37,711 Serious Adverse Events between 2005 and July 2025. This translates to an alarming average of over one death and more than five serious adverse events reported daily.
Compensation Mechanisms Under Scrutiny
One of the most pressing issues highlighted by SAM is the inadequacy of compensation for affected individuals and their families. The group pointed out that only a small percentage of those impacted have received compensation, raising serious doubts about the transparency and effectiveness of the existing compensation mechanisms.
Concerns Regarding Contract Research Organizations
Additionally, SAM has raised alarms about Contract Research Organizations (CROs) that work on behalf of multinational pharmaceutical companies. They allege that these CROs are recruiting vulnerable populations without implementing necessary safeguards or ensuring adequate compensation for participants.
Calls for Action
In light of these findings, SAM is advocating for several key reforms. They emphasize the need for:
- Strengthened accountability and transparency in the conduct of clinical trials.
- Strict enforcement of existing regulations to safeguard participant rights.
- Genuine informed consent processes that truly reflect the participants’ understanding and autonomy.
- Establishment of a compensation mechanism that is fair, timely, and transparent.
Conclusion
The call from SAM for greater transparency and accountability in clinical trials underscores the essential need for ethical oversight in medical research. As clinical trials continue to play a pivotal role in advancing medical science, ensuring the safety and rights of participants must remain a priority. The organization’s advocacy serves as a crucial reminder of the ongoing challenges in the field and the importance of maintaining rigorous standards in clinical ethics.
- Key Takeaways:
- SAM has highlighted ongoing gaps in the regulatory framework for clinical trials.
- Alarming statistics reveal a high number of reported deaths and serious adverse events.
- Compensation mechanisms for affected individuals need significant improvement.
- Vulnerable populations are particularly at risk during clinical trials conducted by CROs.
- Advocating for stricter regulations and genuine informed consent is essential for participant protection.
Read more → www.thehindubusinessline.com